Sanofi's Bioverativ bet pays off with Altuviiio but stumbles on riliprubart

Sanofi’s acquisition of Bioverativ for $11.6 billion in 2018 has delivered a major success with Altuviiio. The drug, approved in 2023 for haemophilia A, has become a blockbuster, achieving around €325 million in sales in the first quarter of 2026. Yet, the overall deal’s success remains uncertain after a recent setback with another treatment, riliprubart. The Bioverativ purchase brought several experimental treatments to Sanofi. Altuviiio has proven its value, becoming a leading therapy in rare diseases. Another drug from the acquisition, Enjaymo, was approved in 2022 but later sold to Recordati.

Riliprubart, a C1s inhibitor designed for chronic inflammatory demyelinating polyneuropathy (CIDP), faced a major hurdle. Sanofi halted the Phase 3 MOBILIZE study after the drug showed ineffectiveness. The company is now reviewing all ongoing trials involving riliprubart to assess its future. Altuviiio’s strong sales confirm part of the Bioverativ deal’s potential. However, the failure of riliprubart raises questions about the full return on Sanofi’s $11.6 billion investment. The company must now decide the fate of other studies tied to the abandoned treatment.